QC
ADMA icon

Quadrature Capital’s ADMA Biologics ADMA Stock Holding History

Quadrature Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Sell
81,677
-122,798
-60% -$1.12M 0.01% 886
2026
Q1 		$1.84M Buy
+204,475
New +$3.23M 0.02% 402

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrature Capital's ADMA Position: Q2 2026 in Review

Quadrature Capital reduced its ADMA Biologics (ADMA) stake by 60% in Q2 2026, selling an estimated $1.12M and leaving 81,677 shares worth $684K. The position accounts for 0.01% of the portfolio, ranked #886.

Quadrature Capital first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.84M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Quadrature Capital held 81,677 shares of ADMA Biologics worth $684K as of Q2 2026.
  • Quadrature Capital sold 122,798 ADMA Biologics shares in Q2 2026, an estimated $1.12M.
  • ADMA Biologics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #886 holding.
  • Quadrature Capital first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • Quadrature Capital's ADMA Biologics position peaked at $1.84M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.